Traumatic Brain Injury Rehabilitation Research

Dr. Eugenio Rocksmith, co-director of the Traumatic Brain Injury Rehabilitation Program, and Dr. Jacqueline Weaver, Clinical Neuropsychologist, are about to join a multicenter clinical trial on the safety and efficacy of a novel pharmacologic medication for the treatment of neurobehavioral disinhibition in outpatients with traumatic brain injury.

Sponsored by Avanir Pharmaceuticals, this will be a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide/quinidine sulfate) for the treatment of neurobehavioral disinhibition including aggression, agitation, and irritability in patients with traumatic brain injury (TBI).

Please check back for updates on this planned work.